Unión Europea - español - EMA (European Medicines Agency)

chiesi farmaceutici spa - citrato de cafeína - la apnea - psychoanaleptics, - el tratamiento de la apnea primaria de los recién nacidos prematuros.

Unión Europea - español - EMA (European Medicines Agency)

gennisium pharma - citrato de cafeína - la apnea - psychoanaleptics, - el tratamiento de la apnea primaria de los recién nacidos prematuros.

Unión Europea - español - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propanediol monohidrato - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas en diabetes - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. además de otros productos medicinales para el tratamiento de la diabetes tipo 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 y 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Unión Europea - español - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propanediol monohidrato - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas en diabetes - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. además de otros productos medicinales para el tratamiento de la diabetes tipo 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 y 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Unión Europea - español - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas en diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 y 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Unión Europea - español - EMA (European Medicines Agency)

astra zeneca ab - saxagliptin, dapaglifozina propanodiol monohidrato - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - drogas usadas en diabetes - qtern, la combinación de dosis fija de saxagliptina y dapaglifozina, está indicado en adultos mayores de 18 años con diabetes mellitus tipo 2:para mejorar el control glucémico cuando la metformina y/o sulfonilureas (su) y uno de los monocomponents de qtern no proporcionan un adecuado control de la glucemia,cuando ya están siendo tratados con la combinación libre de dapaglifozina y saxagliptina. (ver secciones 4. 2, 4. 4, 4. 5 y 5. 1 para los datos disponibles sobre las combinaciones estudiadas.

Unión Europea - español - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-ácido piroglutámico - diabetes mellitus, tipo 2 - drugs used in diabetes, sodium-glucose co-transporter 2 (sglt2) inhibitors - steglatro está indicado en adultos mayores de 18 años con diabetes mellitus tipo 2 como un complemento a la dieta y el ejercicio para mejorar el control de la glucemia:como monoterapia en pacientes para los que el uso de metformina se considera inadecuado debido a la intolerancia o contraindicaciones. además de otros productos medicinales para el tratamiento de la diabetes.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - azacitidina - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agentes antineoplásicos - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - azacitidina - polvo para suspensiÓn inyectable - 100 mg - azacitidina 100 mg - azacitidina

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

zentiva k.s. - azacitidina - polvo para suspensiÓn inyectable - 100 mg - azacitidina 100 mg - azacitidina